1.Efficacy of Cerebellar Transcranial Magnetic Stimulation in Treating Essential Tremor: A Randomized, Sham-Controlled Trial
Ahmad Farag Ibrahim EL-ADAWY ; Mohamed Al-Bahay M. G. REDA ; Ali Mahmoud AHMED ; Mohamed Hamed RASHAD ; Mohamed Ahmed ZAKI ; Mohie-eldin Tharwat MOHAMED ; Mohammad Ali Saeed HASSAN ; Mohammad Fathi ABDULSALAM ; Abdelmonem M HASSAN ; Ahmed Fathy MOHAMED ; Abdel-Ghaffar Ismail FAYED ; Mostafa MESHREF ; Fathy Mahmoud MANSOUR ; Ahmed E. SARHAN ; Ahmed Hassan ELSHESHINY ; Elsayed ABED
Journal of Clinical Neurology 2024;20(4):378-384
Background:
and Purpose Repetitive transcranial magnetic stimulation (rTMS) of the cerebellar hemisphere represents a new option in treating essential tremor (ET) patients. We aimed to determine the efficacy of cerebellar rTMS in treating ET using different protocols regarding the number of sessions, exposure duration, and follow-up duration.
Methods:
A randomized sham-controlled trial was conducted, in which 45 recruit patients were randomly allocated to 2 groups. The first (active group) comprised 23 patients who were exposed to 12 sessions of active rTMS with 900 pulses of 1-Hz rTMS at 90% of the resting motor threshold daily on each side of the cerebellar hemispheres over 4 weeks. The second group (sham group) comprised 22 patients who were exposed to 12 sessions of sham rTMS. Both groups were reassessed at baseline and after 1 day, 1 month, 2 months, and 3 months using the Fahn-Tolosa-Marin tremor-rating scale (FTM).
Results:
Demographic characteristics did no differ between the two groups. There were significant reductions both in FTM subscores A and B and in the FTM total score in the active-rTMS group during the period of assessment and after 3 months (p=0.031 and 0.011, respectively).However, subscore C did not change significantly from baseline when assessed at 2 and 3 months (p=0.073 and 0.236, respectively). Furthermore, the global assessment score was significantly higher in the active-rTMS group (p>0.001).
Conclusions
Low-frequency rTMS over the cerebellar cortex for 1 month showed relative safety and long-lasting efficacy in patients with ET. Further large-sample clinical trials are needed that include different sites of stimulation and longer follow-ups.